Initial data from the Phase 1 dose escalation trial in 18 patients with advanced solid tumors shows AMV564 administered subcutaneously was well tolerated, with no dose-limiting toxicities AMV564...

Amphivena Therapeutics, a clinical-stage immuno-oncology company focused on developing immunotherapeutics that restore anti-cancer immunity to the patient, today announced that Curtis Ruegg,...

Gracell Biotechnologies Co., Ltd. ("Gracell"), a clinical-stage immune cell and gene therapy company, today announced that two presentations were accepted at the 2020 American Society of Clinical...

Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, will present results from a study today that characterize KRAS mutations in...

Tolero Pharmaceuticals, Inc., a clinical-stage company focused on developing novel therapeutics for hematological and oncological diseases, today presented data from the first clinical studies...